TP53 and neoplasm: Finding KSHV orf25, which was not nearly as potent a p53 inhibitor as the tumor-derived dominant negative p53-273 mutant, validated the sensitivity of the screen, and conversely KSHV orf25 as a p53 interacting viral protein.